Panacea Plant Sciences

Village Farms International, Inc. (NASDAQ:VFF) and Hemp for Victory filed a joint motion seeking to disqualify the Drug Enforcement Administration (DEA) from defending the proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. The parties argue that...

A Washington-based researcher has filed a lawsuit against the Drug Enforcement Administration (DEA), alleging multiple legal violations in the agency's process of rescheduling marijuana. As Forbes reported, the complaint, filed in the U.S. District Court for Western Washington, names the Department...

In a significant development for psychedelics research, a Drug Enforcement Administration (DEA) administrative law judge has rejected the agency's request to block key witnesses and evidence in an upcoming hearing. The case, set for November, challenges the DEA's proposed ban on two psychedelic...

The Drug Enforcement Administration (DEA) is pulling back efforts to list certain hallucinogens as Schedule I substances after being challenged by scientists. “DOI and DOC are incredible tools for research, as well as mental and physical health,” Panacea Plant Sciences CEO David...

The DEA recently abandoned a proposal for placing five tryptamines as Schedule I under the Controlled Substances Act. Yet the agency is pushing forward to veto two psychedelic drugs named DOI and DOC with dubious evidence of their potentially nocive effects, as first reported by Psychedelic...